Kaletra Scripts Outpace Sales; Abbott Expects 10% Sales Growth
Executive Summary
Prescriptions for Abbott's protease inhibitor Kaletra are outpacing the product's sales growth
You may also be interested in...
Abbott Rx Business Reaches Maturity With Hospital Products Spin-Off Plan
Abbott's spin-off of the hospital products business indicates that the company is confident it has emerged as a top-tier R&D-driven pharmaceutical company
Bristol Reyataz To Launch In July; Lipid Data Included In Labeling
Bristol-Myers Squibb will make Reyataz (atazanavir) available in July following the June 20 approval of the HIV treatment
Humira Takes Nearly 20% Of Enbrel Share; Abbott Eyes Psoriasis Market Next
Abbott sees psoriasis as the next large market opportunity for Humira after rheumatoid arthritis, Immunology General Manager Tim Walbert said during Abbott's R&D Day in New York May 29